Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT05932212

AK104 for Recurrent or Metastatic Vulvar Cancer

Conditions: Vulvar Cancer

Sex: Female
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Akeso

Location: Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital Fuzhou Fujian

Summary

This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.

Eligibility Criteria

Inclusion Criteria: Age \>=18 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05932212). StuddyBuddy aggregates publicly available trial information.